IMBiologics (KRX: 493280)

Suwon-si, South Korea · Founded 2020 · Publicly Held

IMBiologics Corp is a next-generation biopharmaceutical company developing antibody therapeutics. IMBiologics (KRX: 493280) is based in Suwon-si, South Korea and was founded in 2020. It is now publicly traded; this page covers its private-market history, where its last recorded valuation was $262 million (Mar 2026). It has raised $99.1 million.

Last price · $/share

—

Implied valuation

$261.7M

Total raised

$99.1M

Last round

—

How much has IMBiologics (KRX: 493280) raised?

$99.1Macross 0 recorded rounds

Free account

More of IMBiologics (KRX: 493280) with a free account

·The complete investor list: 22 names
·Watch IMBiologics (KRX: 493280): the Monday email on marks, rounds and moves

Create free account

No card required

Membership and data by Private Market View

IMBiologics (KRX: 493280) investors

22 investors are on record for IMBiologics (KRX: 493280), including KB Investment, Korea Development Bank, IMM Investment and Shinhan Venture Investment. By type, the record holds 5 venture capital firms and 1 asset manager.

For fundraisers

Raising for a company like IMBiologics (KRX: 493280)?

22 investors have backed IMBiologics (KRX: 493280).

See all 22 investors →

Frequently asked about IMBiologics (KRX: 493280)

How much has IMBiologics (KRX: 493280) raised?: IMBiologics (KRX: 493280) has raised $99.1M in total across 0 recorded funding rounds.